Navigation Links
FDA Accepts Cell Therapeutics' Zevalin sBLA and Grants Priority Review
Date:12/1/2008

SEATTLE, Dec. 1 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) announced today that the U.S. Food and Drug Administration (FDA) has accepted for filing and review, and has granted priority review status for, the supplemental Biologics License Application (sBLA) for use of Zevalin(R) ([90Y]-ibritumomab tiuxetan) as consolidation therapy for patients with follicular B-cell non-Hodgkin's lymphoma who achieve a response to first-line therapy. Priority review is granted by the FDA for a treatment that addresses a significant unmet medical need. A Prescription Drug User Fee Act (PDUFA) target date of April 2, 2009 has been established by the FDA for a decision regarding the approval of the Zevalin sBLA. If approved, Zevalin would be the first radioimmunotherapy available to patients as first-line consolidation therapy. It is estimated that there would be approximately 18,000 additional patients that currently receive first-line treatment which would potentially be eligible to use Zevalin under the proposed expanded label.

CTI and Spectrum Pharmaceuticals, Inc. entered into an agreement to form a 50/50 owned joint venture, RIT Oncology LLC, on November 26, 2008 to commercialize and develop ZEVALIN in the United States and expects the transaction will close in early December, 2008. CTI initially acquired the US rights to Zevalin from Biogen Idec in December 2007. CTI gained access to the First-line Indolent Trial (FIT) data through an agreement with Bayer Schering Pharma AG, Germany who used the data to obtain approval for Zevalin as first-line consolidation treatment in Europe.

"We are pleased that the FDA, by granting the application priority review status, acknowledges that the use of Zevalin in the first-line consolidation setting could represent an important treatment option for follicular B-cell non-Hodgkin's lymphoma patients," said James A. Bianco, M.D., CEO of Cell Therapeutic
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. NYSE Alternext US Accepts China Shenghuos Compliance Plan for Continued Listing
2. FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure From ARCA biopharma
3. GSI Group Accepts Shares in Tender Offer for Excel Technology and Commences Subsequent Offering Period
4. Hologic, Inc. Accepts Shares of Third Wave Technologies, Inc. in Tender Offer and Commences Subsequent Offering Period
5. FDA Accepts Immucors Response to Warning Letter
6. FDA Accepts Zingo(TM) Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults
7. U.S. Government Accepts $192 Million of sanofi pasteur H5N1 Bulk Vaccine Antigen for Pandemic Stockpile
8. Imaging Diagnostic Systems Accepts Resignations of Outside Directors
9. EMEA Accepts for Review Vidaza(R) Marketing Authorization Application for Higher-Risk Myelodysplastic Syndromes
10. FDA Accepts Ranexa(R) sNDA and NDA for Filing
11. FDA Accepts Sucampos sNDA for Lubiprostone (8 mcg) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... The ability to see through organs and even the ... well as fine-grained cellular structures has been a long-time ... Press July 31st in the journal Cell ... simple methods for making opaque organs, bodies, and human ... connections intact. The protocols could pave the way for ...
(Date:7/31/2014)... Colo. , July 31, 2014 ... awardee today with $25,000 to fund a translational ... inception in 2011, the gift was presented at ... Annual Meeting in Colorado Springs, ... specialize in neurointerventional approaches to neurovascular conditions, SNIS ...
(Date:7/31/2014)... 2014 Graphite Metallizing Corporation announces ... carts. These bearings are uniquely suited to prevent loss ... because of the high temperatures . , Recently, ... the design engineers at Graphite Metallizing to overcome problems ... their manufacturing operation, pans containing blocks of powder mixture ...
(Date:7/31/2014)... 2014 Research and Markets has ... 2014-2018" report to their offering. ... study of the genetic material or genomes of an ... for the discovery and development of diagnostic and therapeutic ... conditions. Genomics is supported by three major product segments: ...
Breaking Biology Technology:See-through organs and bodies will accelerate biomedical discoveries 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 2SNIS Foundation Bestows First Grant Award For Cutting-Edge NeuroInterventional Research 3Graphite Metallizing Announces Bearings for High Temperature Oven Applications 2Graphite Metallizing Announces Bearings for High Temperature Oven Applications 3Global Genomics Market 2014-2018: Key Vendors are F. Hoffmann-La Roche, Life Technologies, Qiagen and Illumina 2
... of Magainins, the first of a new class of anti-infectives, ... advise Company on pexiganan ... Bulletin Board: MACM) today announced that following its,acquisition of rights ... Board. Dr. Zasloff discovered magainins in,the skin of the African ...
... 24, at 1:30 p.m. EDT, ALAMEDA, Calif., ... a biopharmaceutical company developing innovative therapies,for the treatment ... to discuss third quarter results on Wednesday, October ... Kenneth Chahine, Chief Executive,Officer, and Michael Coffee, Chief ...
... Kyphon Inc.,(Nasdaq: KYPH ) announced today that its ... Inc. (NYSE: MDT ) at a special,meeting of ... 26, 2007, Kyphon entered into a,definitive merger agreement with ... the outstanding shares of Kyphon common stock for,$71.00 per ...
Cached Biology Technology:MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 2MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 3MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 4MacroChem Announces Michael Zasloff, M.D., Ph.D. Joins Company's Scientific Advisory Board 5Avigen, Inc. Announces Third Quarter 2007 Earnings Conference Call 2Kyphon Stockholders Approve Merger with Medtronic 2
(Date:7/31/2014)... United States, natural-gas production from shale rock has ... Yet scientists still do not fully understand the ... a report in the journal Frontiers in ... extraction continues to vastly outpace scientific examination, a ... and institutions, including Princeton University, concluded that determining ...
(Date:7/31/2014)... nearly 3,000 genes to the earliest common ancestor ... have created an extensive "Tree of Lepidoptera" in ... sequencing. , Among the study,s more surprising ... moths than to large ones, which completely changes ... also found that some insects once classified as ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
Breaking Biology News(10 mins):'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 2'Fracking' in the dark: Biological fallout of shale-gas production still largely unknown 3UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3
... ANN ARBOR, Mich.---University of Michigan School of Dentistry has ... may be the largest clinical study to date using genetic ... William Giannobile, professor at U-M dentistry and director of the ... Dentistry, will lead the study for U-M. "It,s ...
... and Building Media Inc. (BMI), a DuPont subsidiary, will ... help dramatically improve the energy efficiency of American homes ... 15 teams, appointed by the U.S. Department of Energy ... million for the initial 18 months to deliver innovative ...
... July 27, 2010 Innovotech Inc. (TSX-V: IOT), a pioneer ... exclusive distribution agreement with LevPharm Ltd of Israel to market ... within Israel. "We are very excited to enter into ... bioFILM PA test can have on improving patient care while ...
Cached Biology News:Landmark dental school study uses genetic test to help predict gum disease 2NJIT to help lead public/private partnership to develop high-efficiency homes 2
KAI 1 (G-2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Anti-OSMR Monoclonal Antibody Research Focus: cytokine/growth factor Storage: 4C Shipping Temperature: 4C...
... are designed for use with the ProQuest ... MaV203 contains deletions in the endogenous GAL4 ... two-hybrid systems. The strain also has leu2 ... bait and prey vectors. MaV203 contains three ...
Biology Products: